|
A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors. Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors. Clinical research trials and A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors. health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors.. A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors. Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors. clinical trial. Human subjects often get the best healthcare possible for their A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors. condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors.  A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors.
A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors.
For Condition: Advanced Solid Tumors
Status: No longer recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: The purpose of this study is to compare two capsules of an investigational drug made by slightly different methods. This will be done by giving the drug made by the two different methods to patients orally and testing blood levels.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: (Subjects must meet the following criteria in order to be eligible for this study.) - Written informed consent - At least 18 years old. - Patients with confirmed advanced solid tumors. - No prior chemotherapy within 5 years of the diagnosis of SCLC (small cell lung cancer). - At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery. - Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function. Exclusion criteria: (Subjects cannot meet the following criteria in order to be eligible for this study.) - Women who are pregnant or lactating. - Patients of child bearing potential refusing to practice adequate contraception. - Patients with uncontrolled vomiting. - Active infection. - Patients with clinical evidence of any gastrointestinal (GI) conditions which would alter GI absorption or GI motility. - Patients requiring treatment with Cyclosporin A. - Severe medical problems other than the cancer, that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk. - Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for cancer treatment. - Use of investigational drug within 30 days prior to the first dose of study medication.
Total Enrollment:
Location and Contact Information:
Study Site
San Antonio, Texas, 78229
United States
Study Site
Philadelphia, Pennsylvania, 19111
United States
Study Site
Nashville, Tennessee, 37203-1632
United States
Study Site
Ottawa, Ontario, K1H 1C4
Canada
Additional Information:
Study ID Numbers: 104864-A/565;
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046111
Other Advanced Solid Tumors Studies:
1. Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors
2. A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors.
3. Study of E7389 in Patients with Advanced Solid Tumors
Related Studies:
Other Advanced Solid Tumors Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors.
|
|
|
|
|
|
|
|
